• IMV Inc (TSX:IMV) has announced that the company will present at the 2020 BIO CEO and Investor Conference next month.
  • Management team members will give the presentation on February 10th, at the Marriott Marquis Hotel in New York.
  • A live webcast and replay of the presentation will be accessible online.
  • IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

Representatives from biopharmaceutical company IMV Inc (IMV) will give a presentation at the BIO CEO and Investor Conference in February. The two-day conference will take place at the Marriott Marquis Hotel in New York City.

The occasion will bring together investors, industry analysts, and senior executives from biotechnology companies. The event is a great opportunity to let investors know about the novel class of immunotherapies which IMV is currently pioneering.

The conference will take place on February 10th and 11th, with company presentations on both days. IMV’s presentation is scheduled for Monday February 10th, at 9:30am Eastern Standard Time.

A live webcast of the presentation will be made available on the investors section of IMV’s website, under Events, Webcasts, and Presentations.

A replay will also be accessible, roughly one hour after the presentation. It will continue to be available for approximately 30 days.

IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

More From The Market Online
WELL Health founder and CEO Hamed Shahbazi, centre.

WELL subsidiary launches support for women’s hormonal imbalance

WELL Health (TSX:WELL) subsidiary Wisp, the United States' largest dedicated women's telehealth provider, launches a weight care vertical.
Stock image generated with AI

Buzz on the Bullboards: Stocks to watch as TSX hits new highs

The TSX experienced a roller-coaster of wins and losses this week, yet managed to break a record high with three companies standing out.
AI healthcare technology

The 10 best AI healthcare stocks to watch

Read about the strong contingent of healthcare stocks keen on applying AI technology to improve patient outcomes.
image of scientist looking into a microscope

BriaCell Therapeutics advances Phase 3 MBC clinical study

BriaCell Therapeutics (TSX:BCT) advances its Phase 3 study of Bria-IMT patients with metastatic breast cancer.